Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2020 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Refer a friend or colleague
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Drugs to avoid in the name of better patient care: 2020 update The independent French medical journal Prescrire's annual review of drugs to avoid includes documented cases of 105 drugs authorised in the European Union that are more dangerous than beneficial. The aim is to make it easier to choose safe, effective treatments, primarily to avoid exposing patients to unacceptable harms. 1 February 2020

Annual Prescrire Drug Awards announced in Paris: 6 winning drugs, but no "Pilule d'Or" The independent French medical journal Prescrire announced its Drug Awards for 2019, at its yearly awards ceremony in Paris on 30 January. Three drugs made the "Honours List" and three others were recognised as "Noteworthy", but there was no "Pilule d'Or" (Golden Pill) awarded this year. 1 February 2020

The Prescrire Packaging Awards for 2019: one winner and plenty of losers The independent French medical journal Prescrire held its annual awards ceremony in Paris on 30 January. A Prescrire Packaging Award recognised Isentress° granules for oral suspension (raltegravir) for its clear, informative instruction booklet, whereas 34 "Red Cards" were handed out for substandard or dangerous packaging. 1 February 2020

Prescrire's Information Awards for 2019: just 6 drug companies (out of 112 contacted) are honoured for the quality of information provided Prescrire's annual Information Awards recognise drug companies which respond to Prescrire's requests with complete and relevant information. In 2019, only a half-dozen drug companies (out of 112 companies contacted by Prescrire's editors with information requests) embraced transparency, in the best interest of patients. 1 February 2020

Baclofen (Baclocur°) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption FEATURED REVIEW The GABA analogue baclofen (Baclocur°, Ethypharm), used since the 1970s as a muscle relaxant, has now been granted marketing authorisation in France for the reduction of alcohol consumption in alcohol-dependent patients in whom the other drug treatments have failed. What is known about baclofen's harm-benefit balance in this clinical situation as of late 2019? Full review (4 pages) available for download by subscribers. 1 February 2020

In the February issue of Prescrire International - High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants FREE DOWNLOAD In the Adverse Effects section this month: should patients taking a direct oral anticoagulant switch to a vitamin K agonist such as warfarin, in light of the French drug regulatory agency's recent advisory? Full text available for free download. 1 February 2020

SSRI antidepressants: persistant sexual dysfunction Antidepressants known as selective serotonin reuptake inhibitors (SSRIs) expose patients to sexual adverse effects that may persist long after discontinuation of the drug. 1 February 2020

Severe vomiting in pregnancy: the priority is to rehydrate In cases of severe nausea and vomiting during pregnancy, priority treatment combines parenteral rehydration and rest. 1 February 2020

Oral desensitisation to peanuts: too many adverse effects Oral desensitisation to peanuts increases rather than reduces the risk of subsequent serious allergic reactions. 1 February 2020

Antiepileptics and pregnancy: potential long-term effects in children FEATURED REVIEW Many women who could become pregnant are exposed to antiepileptic drugs. Yet most of the antiepileptic drugs taken by pregnant women expose the unborn child to the risk of malformations, fetotoxic effects and neonatal disorders. What are the long-term effects of the most widely used antieleptics on children exposed in utero, and how do they compare? Full review (8 pages) available for download by subscribers. 1 January 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

• Sitemap |
• Terms of use |
• Contact
• |Top of page